Legend Biotech Corporation - American Depositary Shares (LEGN) Covered Calls
You can sell covered calls on Legend Biotech Corporation - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LEGN (prices last updated Fri 4:16 PM ET):
| Legend Biotech Corporation - American Depositary Shares (LEGN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 34.08 | +0.06 | 32.90 | 35.00 | 1.6M | - | 4.5 |
| Covered Calls For Legend Biotech Corporation - American Depositary Shares (LEGN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Jan 17 | 35 | 1.70 | 33.30 | 5.1% | 64.2% | |
| Feb 21 | 35 | 2.70 | 32.30 | 8.4% | 47.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
| Top 10 Open Interest For Jan 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | INTC covered calls | 1. | RGTI covered calls | |
| 2. | SLV covered calls | 7. | SPY covered calls | 2. | NMRA covered calls | |
| 3. | AAPL covered calls | 8. | TSLA covered calls | 3. | HUMA covered calls | |
| 4. | EEM covered calls | 9. | IWM covered calls | 4. | DLO covered calls | |
| 5. | XLF covered calls | 10. | TLT covered calls | 5. | MARA covered calls | |
Want more examples? LEG Covered Calls | LEMB Covered Calls
